RUA Life Sciences has announced preliminary results for the year to March 22, in line with the May 22 Trading Update. Revenues grew 6% to £1.6m with an operating loss of £2.4m. Fiscal year-end cash was £3.0m. At the division level, the company continues to make progress with its vascular graft programme, targeting regulatory approvals in late 2024 and market entry during 2025. Both RUA Biomaterials and RUA Medical Devices division had strong years with underlying volumes up for Biomaterials and ....
